November 17, 2023 — It’s not easy. Getting access to good obesity care and maintaining it is a challenge that is especially frustrating as we see that the options for care are improving. But it seems that health systems right now are rigged to interrupt obesity treatment. An illustration of this comes from a recent study published in Obesity. […]
August 11, 2023 — Calm in the midst of a storm is always odd. Has it passed? Or is there more to come? Bedlam pretty much defines the market for obesity care right now. Both Novo Nordisk and Lilly announced robust business results on the strength of impressive new options for treating obesity. Novo released stunning topline results for […]
August 3, 2023 — Message to University of Texas Employees: Continuing to pay for obesity medicines is unsustainable. Message from Novo Nordisk: No comment. Price shocks for advanced obesity medicines are hitting employers. Things are starting to get messy in the marketplace and you can be pretty sure that they will only get messier as makers of obesity medicines […]
March 14, 2023 — Recently, we have written much about the high cost of obesity medicines, limited coverage under health plans, and the need for change. This is a very real problem and glaciers melt faster (sad to say) than policy makers make progress on this. But absurd arguments about the cost of obesity care do not help. In […]
